| 12/06/25 | GSK | 11:00:00 | 12 Jun 2025 | | GSK | Director/PDMR Shareholding | GSK plc | PRN |
| 27/05/25 | GSK | 07:00:11 | 27 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 23/05/25 | GSK | 12:16:16 | 23 May 2025 | | GSK | positive CHMP opinion on Blenrep in EU | GSK PLC | RNS |
| 23/05/25 | GSK | 07:00:05 | 23 May 2025 | | GSK | FDA approves Nucala COPD indication | GSK PLC | RNS |
| 23/05/25 | GSK | 07:00:05 | 23 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 22/05/25 | GSK | 07:00:04 | 22 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 21/05/25 | GSK | 07:00:05 | 21 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 20/05/25 | GSK | 15:30:01 | 20 May 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 20/05/25 | GSK | 07:00:05 | 20 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 19/05/25 | GSK | 07:00:08 | 19 May 2025 | | GSK | Blenrep for 2L+ multiple myeloma approved in Japan | GSK PLC | RNS |
| 19/05/25 | GSK | 07:00:03 | 19 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 16/05/25 | GSK | 07:00:04 | 16 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 15/05/25 | GSK | 07:00:04 | 15 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 14/05/25 | GSK | 07:00:07 | 14 May 2025 | | GSK | GSK to acquire efimosfermin | GSK PLC | RNS |
| 14/05/25 | GSK | 07:00:04 | 14 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 13/05/25 | GSK | 15:30:01 | 13 May 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 13/05/25 | GSK | 12:56:36 | 13 May 2025 | | GSK | Update on belrestotug development programme | GSK PLC | RNS |
| 13/05/25 | GSK | 07:00:06 | 13 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 12/05/25 | GSK | 15:31:09 | 12 May 2025 | | GSK | Block listing Interim Review | GSK PLC | RNS |
| 12/05/25 | GSK | 07:00:05 | 12 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 09/05/25 | GSK | 07:00:04 | 9 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 08/05/25 | GSK | 17:15:40 | 8 May 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 08/05/25 | GSK | 15:30:01 | 8 May 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 08/05/25 | GSK | 11:15:00 | 8 May 2025 | | GSK | Linerixibat GLISTEN pIII trial data at EASL | GSK PLC | RNS |
| 08/05/25 | GSK | 07:00:06 | 8 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 07/05/25 | GSK | 18:22:09 | 7 May 2025 | | GSK | Result of AGM | GSK PLC | RNS |
| 07/05/25 | GSK | 07:00:06 | 7 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 06/05/25 | GSK | 07:00:11 | 6 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 02/05/25 | GSK | 07:00:03 | 2 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 01/05/25 | GSK | 15:30:00 | 1 May 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 01/05/25 | GSK | 15:00:01 | 1 May 2025 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 01/05/25 | GSK | 07:00:09 | 1 May 2025 | | GSK | Nucala MATINEE data in COPD published in NEJM | GSK PLC | RNS |
| 01/05/25 | GSK | 07:00:06 | 1 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 30/04/25 | GSK | 07:05:01 | 30 Apr 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 30/04/25 | GSK | 07:00:05 | 30 Apr 2025 | | GSK | 1st Quarter Results | GSK PLC | RNS |
| 29/04/25 | GSK | 07:00:07 | 29 Apr 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 28/04/25 | GSK | 07:00:04 | 28 Apr 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 25/04/25 | GSK | 07:00:06 | 25 Apr 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 24/04/25 | GSK | 07:00:07 | 24 Apr 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 23/04/25 | GSK | 07:00:05 | 23 Apr 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 22/04/25 | GSK | 07:00:09 | 22 Apr 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 17/04/25 | GSK | 16:13:50 | 17 Apr 2025 | | GSK | Blenrep licensed by UK MHRA | GSK PLC | RNS |
| 17/04/25 | GSK | 15:30:00 | 17 Apr 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 17/04/25 | GSK | 07:10:01 | 17 Apr 2025 | | GSK | Arexvy now ACIP recommended for 50-59 at risk | GSK PLC | RNS |
| 17/04/25 | GSK | 07:05:00 | 17 Apr 2025 | | GSK | GSK 5-in-1 meningitis vaccine recommended in US | GSK PLC | RNS |
| 17/04/25 | GSK | 07:00:05 | 17 Apr 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 16/04/25 | GSK | 07:00:07 | 16 Apr 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 15/04/25 | GSK | 15:30:00 | 15 Apr 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 15/04/25 | GSK | 07:00:04 | 15 Apr 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 14/04/25 | GSK | 07:00:06 | 14 Apr 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |